Skip to main content

Table 1 Patient characteristics at baseline

From: Polymyxin B-immobilized fiber column hemoperfusion mainly helps to constrict peripheral blood vessels in treatment for septic shock

Case number 78 patients
Sex (male/female) 50/28
Age (years) 70 (20–87)
APACHE II score 24 (3–38)
SOFA score 11 (0–19)
MAP before the PMX treatment (mmHg) 64 (40–104)
CVP before the PMX treatment (mmHg) 15 (12–22)
Creatinine before the PMX treatment (mg/dl) 1.42 (0.41–10.24)
Endotoxin level before the PMX treatment (pg/mL) 11.3 (0.8–1925)
Lactate level before the PMX treatment (mmol/L) 3.7 (1.0–23.0)
Patients with diabetes mellitus 24
Patients received corticosteroid therapy 13
The times of PMX therapy 1 (1–6)
Total PMX treatment time (min) 1456 (80–18,100)
Suspected causative microorganisms
  GNR 41
  GPC 12
  GPR 2
  Unknown origin 23
Infection site
  Abdomen 27
  Bloodstream 15
  Lung 10
  Urinary tract 6
  Others (unknown origin) 20
  1. Data are presented as number of cases or median (range). MAP mean arterial pressure, CVP central venous pressure, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, PMX polymyxin B-immobilized fiber column hemoperfusion, GNR Gram-negative rods, GPC Gram-positive cocci, GPR Gram-positive rods.